Clinical Trials at Duke Cancer Center
As of August 2026, 30 paid clinical trials are recruiting at Duke Cancer Center, located at ERWIN ST, DURHAM, NC 27710-0001, phone (919) 698-2149 in Durham, North Carolina. Active studies at this site cover conditions such as Heart Failure, Breast Cancer and Prostate Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Durham
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery
32 clinical trials at Duke Cancer Center
·Clear filters·Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking
Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients
Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
Common conditions studied in Durham
- Heart Failure (20 active studies)
- Breast Cancer (19 active studies)
- Prostate Cancer (16 active studies)
- Cancer (12 active studies)
- Acute Myeloid Leukemia (11 active studies)
- Stroke (11 active studies)
Leading research sponsors in Durham
- Duke University
- VA Office of Research and Development
- National Cancer Institute (NCI)
- AstraZeneca
- Children's Oncology Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Durham?
There are approximately 1,044 recruiting clinical trials in Durham, North Carolina listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Durham pay participants?
Most recruiting trials in Durham compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Durham?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Durham?
The most common conditions under active study in Durham include Heart Failure (20), Breast Cancer (19), Prostate Cancer (16), Cancer (12), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Durham?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Durham on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Durham?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Durham?
Recruiting research sites in Durham include Duke University Medical Center, Duke University, Duke University Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Durham right now?
The largest active categories in Durham are Cancer & tumors (286), Cardiovascular (95), Neurology & pain (67). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Duke Cancer Center?
Duke Cancer Center is located at ERWIN ST, DURHAM, NC 27710-0001. Use the Google Maps link in the intro above to get directions.
How do I contact Duke Cancer Center?
You can reach Duke Cancer Center by phone at (919) 698-2149. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.